Pratteln, Switzerland Tuesday, January 7, 2025, 11:00 Hrs [IST] ...

Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Clinigen Group to manage the supply and distribution of AGAMREE® (vamorolone) in countries where the product ...

England’s National Institute for Health and Care Excellence (NICE) has recommended Santhera Pharmaceuticals’ treatment for Duchenne muscular dystrophy (DMD) Agamree (vamorolone) following a ...

Santhera partners with Clinigen to supply Agamree for Duchenne muscular dystrophy in regions without commercial availability.

"DMD is a devastating condition affecting over 70,000 families in China, and until now, there had been no approved treatment option for patients," said Dario Eklund, CEO of Santhera. "We are delighted ...

China’s National Medical Products Administration (NMPA) has approved Santhera Pharmaceuticals’ AGAMREE (vamorolone), used to treat Duchenne muscular dystrophy (DMD) in patients aged four years ...

Santhera Receives Positive Recommendation from NICE for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy AGAMREE® has been recommended by NICE for treating Duchenne muscular ...

"DMD is a devastating condition affecting over 70,000 families in China, and until now, there had been no approved treatment option for patients," said Dario Eklund, CEO of Santhera. "We are ...

Pratteln, Switzerland, December 11, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces that China’s National Medical Products Administration (NMPA) has approved AGAMREE® (vamorolone ...

Pratteln, Switzerland, December 11, 2024 - Santhera Pharmaceuticals (SIX: SANN) announces that China's National Medical Products Administration (NMPA) has approved AGAMREE® (vamorolone) for use in ...